Bioadaptives (BDPT) Return on Capital Employed (2014 - 2026)

Bioadaptives has disclosed Return on Capital Employed across 11 years of filings, most recently posting 47.4% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 47.4%, down 619.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 47.4% (down 619.0% YoY), and the FY2025 annual result was 49.34%, up 1032.0% from the prior year.
• Return on Capital Employed came in at 47.4% for Q1 2026 at Bioadaptives, down from 47.79% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 81.33% in Q3 2025 to a low of 10.57% in Q2 2023.
• The 5-year median for Return on Capital Employed is 36.32% (2022), against an average of 35.81%.
• Across the five-year window, Return on Capital Employed plunged 3439 bps in 2023 and surged 6555 bps in 2025, its largest moves.
• Bioadaptives' Return on Capital Employed stood at 28.99% in 2022, then plunged by 49 bps to 14.92% in 2023, then surged by 157 bps to 38.31% in 2024, then rose by 25 bps to 47.79% in 2025, then declined by 1 bps to 47.4% in 2026.
• The last three Return on Capital Employed figures came in at 47.4% (Q1 2026), 47.79% (Q4 2025), and 81.33% (Q3 2025), per Business Quant data.